Deferring upfront CNS-directed radiation in EGFR-variant and ALK-positive NSCLC may improve outcomes but raises treatment-related toxicity risks.

U.S. FDA Grants Full Approval of VITRAKVI® (larotrectinib) for Adult and Pediatric Patients with NTRK Gene Fusion-Positive ...

This oncogenic fusion drives aberrant tyrosine kinase activity ... T-cell lymphomas exhibit diverse genetic aberrations, with ALK rearrangements defining anaplastic large cell lymphoma.

LUAD is frequently associated with mutations in EGFR, KRAS, ALK, and BRAF ... Similarly, targeted treatments such as EGFR tyrosine kinase inhibitors (TKIs) have transformed the therapeutic ...